{"record_key":"kalivir-immunotherapeutics","identifier":"kalivir-immunotherapeutics","external_key":null,"title":"KaliVir Immunotherapeutics","summary":null,"url":"https://inventions.pitt.edu/startups/kalivir-immunotherapeutics","json_url":"https://inventions.pitt.edu/startups/kalivir-immunotherapeutics.json","object_key":"startups","description":"KaliVir Immunotherapeutics is developing next-generation oncolytic viral immunotherapies for cancer. Its Vaccinia Enhanced Template (VET) platform engineers vaccinia viruses that can be delivered intravenously, replicate selectively in tumors, and express therapeutic payloads. [1]: https://kalivir.com/\nThe company was co-founded in 2019 by Stephen Thorne, a former University of Pittsburgh professor of cell biology and immunology who serves as chief scientific officer. In August 2026 it announced the closing of a $14 million Series A extension, and it has a clinical trial collaboration and supply agreement with Roche. [1]: https://kalivir.com/ [2]: https://www.innovation.pitt.edu/featured-startup-kalivir-therapeutics","attributes":[{"key":"website","label":"Website","values":["https://www.kalivir.com"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Oncology"]},{"key":"funding_stage","label":"Funding Stage","values":["Series A+"]},{"key":"founders","label":"Founders","values":["Stephen Thorne"]}],"related":[]}